Skip to main content
ICPE 2023 Main banner
Final Program


ICPE 2023 Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Biologics/Biosimilars

Session: Poster Session A

(038) Real-world evaluation of the persistence of the most used drug groups in Rheumatoid Arthritis from 2017 to 2021 in the Public Health System, Brazil

Friday, August 25, 2023
8:00 AM – 6:00 PM ADT
Location: Convention Hall
Publication Number: 375

    Presenting Author(s)

  • Francisco de Assis Acurcio, ScD

    Full Professor
    Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
    Universidade Federal de Minas Gerais
    Belo Horizonte, Brazil

Background: Rheumatoid Arthritis (RA) is one of the most prevalent chronic inflammatory diseases in the world. Complete remission of the disease is unusual and chronic treatment is usually required. The main objectives of the treatment are to maximize the quality of life of patients, preventing and controlling joint damage, as well as preventing loss of function and reducing symptons.

Objectives: This study aimed to evaluate the persistence of nine groups of drugs most used in the treatment of RA during the cohort period (2017 to 2021).

Methods: The study included several drug groups, including DMard-B-Anti-CD20, DMard-B-Anti-TNF, DMard-B-Anti-FNF + DMard-S-Conv, DMard-B-IL, DMard-B-T- CELL, Dmard-B-T-CELL + Dmard-S-Conv, Dmard-S-Conv, Dmard-S-Conv + Dmard-S-Conv, Dmard-S-JAK and other drug groups. The analyzed events are interruption or change of medication group in the treatment from initiation (time 0) until the first occurrence of the event. The loss of persistence in the use of the medication is an occurrence that can have adverse consequences for the patient's health, being particularly significant in the treatment of chronic diseases. The Kaplan-Meier method was used for assess persistence in the treatment of rheumatoid arthritis in 252,939 patients.

Results: The results showed that the Dmard-B-Anti-CD20 group had the worst persistence rate. The Dmard-S-Conv, Other drug groups, Dmard-S-Conv + Dmard-S-Conv, Dmard-B-T-CELL + Dmard-S-Conv and Dmard-B-Anti-FNF + Dmard-S-Conv groups showed great loss of persistence, reaching rates below 50% before completing the first year of treatment. The other drug groups showed an intermediate persistence curve. The Dmard-B-Anti-TNF and Dmard-B-IL groups showed a higher persistence curve, with Dmard-B-IL showing higher rate than Dmard-B-Anti-TNF.

Conclusions: The best result was obtained with the group of drugs categorized as DMard-S-JAK which are the specific target synthetic drugs.